Sponsored
The CDMO landscape is shifting toward long-term strategic partnerships as drug modalities grow more complex and supply chain pressures mount. Noritsugu Fujita, Division President of Pharmaceutical Solutions Division at Terumo, explains how an integrated, single-source model for parenteral drug development aims to streamline the path to a patient-ready product.
